<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>374</serviceExecutionTime><Drug id="37292"><DrugName>CJV-1001</DrugName><DrugSynonyms><Name><Value>CJV-1001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anticancer therapeutics, ChemGenex/Elan</Value></Name></DrugSynonyms><CompanyOriginator id="15873">Elan Corp plc</CompanyOriginator><CompaniesSecondary><Company id="15873">Elan Corp plc</Company><Company id="29092">ChemGenex Pharmaceuticals Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="37292" type="Drug"><TargetEntity id="311767" type="siDrug">CJV-1001</TargetEntity></SourceEntity><SourceEntity id="15873" type="Company"><TargetEntity id="4295874887" type="organizationId">Perrigo Corporation DAC</TargetEntity></SourceEntity><SourceEntity id="29092" type="Company"><TargetEntity id="4295858213" type="organizationId">Chemgenex Pharmaceuticals Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-23T03:49:12.000Z</LastModificationDate><ChangeDateLast>2007-11-30T11:41:28.000Z</ChangeDateLast><AddedDate>2001-12-08T11:25:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29092" linkType="Company"&gt;ChemGenex Pharmaceuticals&lt;/ulink&gt; was investigating CJV-1001 for the potential treatment of cancer. In December 2001, CJV-1001 was in preclinical development [&lt;ulink linkID="432267" linkType="reference"&gt;432267&lt;/ulink&gt;]; however, no further development was reported and this compound did not appear in the company's pipeline in June 2004, after the merger between ChemGenex and AGT Biosciences [&lt;ulink linkID="545630" linkType="Reference"&gt;545630&lt;/ulink&gt;], [&lt;ulink linkID="545967" linkType="Reference"&gt;545967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15873" linkType="Company"&gt;Elan&lt;/ulink&gt; was originally co-investigating the compound with ChemGenex; however, as of September 2002, Elan had discontinued all oncology programs and was seeking to sell off its oncology assets [&lt;ulink linkID="464870" linkType="reference"&gt;464870&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By April 2001, the compound had shown activity in hematological malignancies and solid tumors [&lt;ulink linkID="432653" linkType="reference"&gt;432653&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2002-09-23T00:00:00.000Z</StatusDate><Source id="464870" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29092">ChemGenex Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-06-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2001-12-08T11:25:18.000Z</StatusDate><Source id="432267" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29092">ChemGenex Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2001-12-08T00:00:00.000Z</StatusDate><Source id="432267" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1091305">Perrigo Co plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110935" title="Elan and Chemgenex to codevelop anticancer therapeutics"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>